Cézard et al25 | 2001 | 172 | 3 months–4 years | 1.5 mg/kg administered orally 3 times daily | Placebo | Inpatient, 13 separate French hospitals | Stated randomised but not method given | Not mentioned | Double blinded | Low risk | All appropriate outcome data | Involvement with pharma not clear, many recruited patients did not meet inclusion |
Gutiérrez-Castrellón et al26 | 2010 | 280 | 1 month–2 years | 1.5 mg/kg administered orally 3 times daily | Placebo | Inpatient, Mexico | Computer generated | Central allocation | Double blinded | Low risk | All appropriate outcome data | Authors confirm no drug company involvement |
Gutiérrez-Castrellón et al 26 | 2010 | 184 | 1 month–2 years | 1.5 mg/kg administered orally 3 times daily | Placebo | Outpatient, Mexico | Computer generated | Central allocation | Double blinded | Low risk | All appropriate outcome data | Authors confirm no drug company involvement |
Salazar Lindo et al27 | 2000 | 135 | 3–35 months | 1.5 mg/kg administered orally 3 times daily | Placebo | Inpatient, Peru | Stated randomised but not method given | Not mentioned | Double blinded | Low risk | All appropriate outcome data | Authors confirm no drug company involvement |
Santos et al28 | 2009 | 189 | 3–36 months | 1.5 mg/kg administered orally 3 times daily | Placebo | Outpatient, single centre, Spain | Computer generated | Not successfully concealed | Open label | One patient's details missing | All appropriate outcome data | Authors confirm no drug company involvement, except in initial design |
Melendez Garcia et al29 | 2007 | 50 | 3–71 months | Not specified | Kaolin/pectin | Outpatient, Guatemala | Stated randomised but not method given | Not mentioned | Unclear how blinded | Not complete | No side effect data | None apparent |
Turck et al30 | 1999 | 102 | 2–10 years | 1.5 mg/kg administered orally 3 times daily | 0.03 mg/kg loperamide | Outpatient, multiple French centres | Stated randomised but not method given | Not mentioned | Double blinded | Low risk | All appropriate outcome data | None apparent |